NASDAQ:REGN • US75886F1075
The current stock price of REGN is 747.36 USD. Today REGN is down by -0.27%. In the past month the price increased by 1.47%. In the past year, price increased by 24.01%.
REGN currently appears in the following ChartMill screener lists.
ChartMill assigns a technical rating of 3 / 10 to REGN. When comparing the yearly performance of all stocks, REGN turns out to be only a medium performer in the overall market: it outperformed 61.36% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to REGN. REGN gets an excellent profitability rating and is at the same time showing great financial health properties.
On January 30, 2026 REGN reported an EPS of 11.44 and a revenue of 3.88B. The company beat EPS expectations (5.66% surprise) and beat revenue expectations (0.21% surprise).
38 analysts have analysed REGN and the average price target is 880.98 USD. This implies a price increase of 17.88% is expected in the next year compared to the current price of 747.36.
For the next year, analysts expect an EPS growth of 5.64% and a revenue growth 11.11% for REGN
Over the last trailing twelve months REGN reported a non-GAAP Earnings per Share(EPS) of 44.38. The EPS decreased by -2.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.41% | ||
| ROA | 11.11% | ||
| ROE | 14.41% | ||
| Debt/Equity | 0.09 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
IPO: 1991-04-02
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591 US
CEO: Leonard S. Schleifer
Employees: 15410
Phone: 17813705000
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
The current stock price of REGN is 747.36 USD. The price decreased by -0.27% in the last trading session.
REGENERON PHARMACEUTICALS (REGN) has a dividend yield of 0.5%. The yearly dividend amount is currently 3.44.
REGN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
REGN stock is listed on the Nasdaq exchange.
38 analysts have analysed REGN and the average price target is 880.98 USD. This implies a price increase of 17.88% is expected in the next year compared to the current price of 747.36.
The PE ratio for REGENERON PHARMACEUTICALS (REGN) is 16.84. This is based on the reported non-GAAP earnings per share of 44.38 and the current share price of 747.36 USD.
